Effects of Yiqi Sanju Formula on non-alcoholic fatty liver disease: a randomized controlled trial
	    		
		   		
	    	
    	
    	
   		
        
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Shaoying LOU
			        		
			        		;
		        		
		        		
		        		
			        		Yi LIU
			        		
			        		;
		        		
		        		
		        		
			        		Yuying MA
			        		
			        		;
		        		
		        		
		        		
			        		Haiying CHEN
			        		
			        		;
		        		
		        		
		        		
			        		Weihua CHEN
			        		
			        		;
		        		
		        		
		        		
			        		Jian YING
			        		
			        		;
		        		
		        		
		        		
			        		Yanming HE
			        		
			        		;
		        		
		        		
		        		
			        		Wenjian WANG
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:Journal Article
 
        	
        	
            
            
            	- From:
	            		
	            			Journal of Integrative Medicine
	            		
	            		 2008;6(8):793-8
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:Chinese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	OBJECTIVE: To observe the therapeutic effects of Yiqi Sanju Formula (YQSJF), a compound traditional Chinese herbal medicine, in treatment of non-alcoholic fatty liver disease (NAFLD). METHODS: Sixty-seven patients diagnosed with NAFLD were randomly divided into two groups: YQSJF-treated group (39 cases) and placebo group (28 cases). The NAFLD patients in the two groups were treated with YQSJF and placebo respectively for 3 months. Clinical symptoms, the CT ratio of liver-spleen, body mass index (BMI), waist circumference, homeostatic model assessment for insulin resistance (HOMA2-IR) and the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor-alpha (TNF-alpha), high sensitivity C-reactive protein (hs-CRP), triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) were evaluated before and after treatment. RESULTS: After treatment, the clinical symptoms were improved and the levels of BMI, waist circumference, HOMA2-IR, ALT, AST, TG and TC were decreased significantly in the YQSJF-treated group (P<0.05). The CT ratio of liver-spleen in the YQSJF-treated group was increased significantly as compared with the placebo group (P<0.01).